Porton Pharma Solutions (XSEC:300363) - Hisse Senedi Fiyatı, Haberler ve Analizler

300363 Stoklara Genel Bakış

Porton Pharma Solutions Ltd. Çin, Amerika Birleşik Devletleri ve Avrupa'daki ilaç şirketlerine küçük moleküllü aktif farmasötik bileşenlerin, dozaj formlarının ve biyolojik ilaçların üretimi ve satışı ile ilgilenmektedir. Daha fazla detay

300363 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	3/6

Ödüller

Kazançların yılda 123.94% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

2.83% temettüsü kazançlar veya serbest nakit akışları tarafından iyi karşılanmıyor

Porton Pharma Solutions Ltd. Rakipler

Youcare Pharmaceutical Group

SHSE:688658

CN¥9.4b

Zhejiang Hisun Pharmaceutical

SHSE:600267

CN¥9.9b

Zhejiang Hisoar Pharmaceutical

SZSE:002099

CN¥9.4b

Xiamen Kingdomway Group

SZSE:002626

CN¥9.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Porton Pharma Solutions
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CN¥17.19
52 Haftanın En Yüksek Seviyesi	CN¥29.50
52 Haftanın En Düşük Seviyesi	CN¥10.91
Beta	0.21
11 Aylık Değişim	-8.12%
3 Aylık Değişim	43.97%
1 Yıllık Değişim	-40.54%
33 Yıllık Değişim	-82.24%
5 Yıllık Değişim	28.19%
Halka arzdan bu yana değişim	-20.27%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	300363	CN Pharmaceuticals	CN Pazar
7D	-5.3%	-1.8%	-2.6%
1Y	-40.5%	-7.0%	4.2%

Getiri vs. Endüstri: 300363 geçen yıl % -7 oranında getiri sağlayan CN Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 300363 geçen yıl % 4.2 oranında getiri sağlayan CN Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 300363's price volatile compared to industry and market?
300363 volatility
300363 Average Weekly Movement	13.0%
Pharmaceuticals Industry Average Movement	7.3%
Market Average Movement	8.4%
10% most volatile stocks in CN Market	12.7%
10% least volatile stocks in CN Market	5.6%

İstikrarlı Hisse Senedi Fiyatı: 300363 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 300363 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala CN hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2005	4,300	Nianfeng Ju	www.porton.cn

Porton Pharma Solutions Ltd. Temel Bilgiler Özeti

Porton Pharma Solutions'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
300363 temel i̇stati̇sti̇kler
Piyasa değeri	CN¥9.38b
Kazançlar(TTM)	-CN¥391.43m
Gelir(TTM)	CN¥2.76b

3.4x

P/S Oranı

-24.0x

F/K Oranı

300363 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
300363 gelir tablosu (TTM)
Gelir	CN¥2.76b
Gelir Maliyeti	CN¥2.22b
Brüt Kâr	CN¥534.89m
Diğer Giderler	CN¥926.32m
Kazançlar	-CN¥391.43m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.72
Brüt Marj	19.41%
Net Kâr Marjı	-14.20%
Borç/Özkaynak Oranı	24.7%

300363 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.8%

Mevcut Temettü Verimi

-68%

Ödeme Oranı

300363 Stoklara Genel Bakış

Ödüller

Risk Analizi

Porton Pharma Solutions Ltd. Rakipler

SHSE:688658

CN¥9.4b

SHSE:600267

CN¥9.9b

SZSE:002099

CN¥9.4b

SZSE:002626

CN¥9.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

New major risk - Revenue and earnings growth

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

New major risk - Revenue and earnings growth

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 16%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Full year 2022 earnings released: EPS: CN¥3.70 (vs CN¥0.97 in FY 2021)

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS: CN¥0.70 (vs CN¥0.16 in 1Q 2021)

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Revenue beats expectations

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13

Investor sentiment improved over the past week

New 90-day high: CN¥39.66

Third quarter earnings released

Porton Pharma Solutions Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Market bids up stock over the past week

New 90-day high: CN¥38.90